Logo for Bavarian Nordic

Bavarian Nordic Investor Relations Material

Latest events

Logo for Bavarian Nordic

Q1 2024

Bavarian Nordic
Logo for Bavarian Nordic

Q1 2024

8 May, 2024
Logo for Bavarian Nordic

Q4 2023

6 Mar, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Bavarian Nordic

Access all reports
Segment Data
Access more data
Revenue by
Products and services
MVA-BN smallpox vaccine
Rabipur/RabAvert
Encepur
Other product sale
Other
Expenses by
Financials
Bavarian Nordic is a clinical-stage biopharmaceutical company that develops and commercializes life-saving vaccines in the areas of cancer and infectious diseases. Its fast-growing portfolio today includes Aeras, an influenza vaccine that has been approved in the United States, Europe, and Canada, and the company is advancing a pipeline of novel, next generation vaccines designed to complement its portfolio. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.